Tang Xu, Guo Na, Xu Lixian, Gou Xingchun, Mi Man
a Department of Pathology, Sichuan College of Traditional Chinese Medicine , Mianyang, China.
b Lab of Cell Biology & Translational Medicine, Xi'an Medical University, Xi'an , China.
J Drug Target. 2013 Apr;21(3):224-231. doi: 10.3109/1061186X.2012.702769. Epub 2012 Aug 29.
Hepatocellular carcinoma (HCC) is characterized by high resistance to conventional systemic therapies, rapid progression, easy metastasis and frequent recurrence. There is therefore an urgent requirement to develop novel systemic agents which specifically target hepatoma-associated antigen in the tumors of HCC patients. CD147, a transmembrane glycoprotein, is highly expressed by HCC cells and is strongly associated with HCC progression and prognosis. CD147 in HCC cells modulates HCC growth, promotes invasion and metastasis by stimulating adjacent fibroblasts and HCC cells to produce elevated levels of several extracellular matrix metalloproteinases (MMPs) in the HCC microenvironment. It is also involved in HCC angiogenesis and multidrug resistance (MDR). Clinical progress has been made in HCC treatment using CD147-directed monoclonal antibodies. Here, we give an overview of the literature regarding the molecular features and expression of CD147 in human HCC tissues. We specifically focus on the role of CD147 in HCC invasion and metastasis, as well as in angiogenesis and multidrug resistance. In addition, advances in therapeutic strategies targeting HCC CD147 are summarized.
肝细胞癌（HCC）的特点是对传统全身治疗具有高度抗性、进展迅速、易于转移且频繁复发。因此，迫切需要开发新型全身治疗药物，专门针对HCC患者肿瘤中的肝癌相关抗原。CD147是一种跨膜糖蛋白，在HCC细胞中高度表达，与HCC的进展和预后密切相关。HCC细胞中的CD147通过刺激邻近的成纤维细胞和HCC细胞在HCC微环境中产生升高水平的几种细胞外基质金属蛋白酶（MMP）来调节HCC生长、促进侵袭和转移。它还参与HCC血管生成和多药耐药（MDR）。使用针对CD147的单克隆抗体在HCC治疗方面已取得临床进展。在此，我们概述了有关人HCC组织中CD147分子特征和表达的文献。我们特别关注CD147在HCC侵袭和转移以及血管生成和多药耐药中的作用。此外，还总结了针对HCC CD147的治疗策略进展。
